bimekizumab 
GtoPdb Ligand ID: 9411
|
Synonyms: CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1
Compound class:
Antibody
Comment: Bimekizumab (UCB4940) is a rat-derived humanized Phase 2 monoclonal antibody targeting both IL-17A and IL-7F (dual antagonist), with potential for controlling autoimmune conditions mediated by these proinflammatory cytokines. Safety, pharmacokinetics and clinical efficacy of bimekizumab in mild psoriasis are reported in [2]. Claimed in patent WO2008047134 as CA028_0496 [1].
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 9878 | bimekizumab |
| Synonyms |
| CA028_0496 | CDP4940 | gL7gH9 | UCB-4940 | UCB4940 | Zu-G1 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 486 |
| Other databases | |
| GtoPdb PubChem SID | 328083513 |
| Search PubMed clinical trials | bimekizumab |
| Search PubMed titles | bimekizumab |
| Search PubMed titles/abstracts | bimekizumab |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License